Fadi Massoud1. 1. Hôpital Notre-Dame, Service de gériatrie, 1560, Sherbrooke Est, Montréal, (Québec) H2L 2M1. fadi-massoud@videotron.ca
Abstract
OBJECTIVE: Alzheimer disease (AD) is the most common form of dementia. There have been many advances in the pharmacological treatment of AD in recent years. This article discusses 2 of these advances: vascular prevention and a new molecule, memantine. QUALITY OF EVIDENCE: The conclusions and recommendations in this article are based on data from studies providing level I and level II evidence. MAIN MESSAGE: Recent data suggest that vascular disease plays an important role in the physiopathology of AD. Memantine is a non-competitive, low-affinity N-methyl-D-aspartate receptor antagonist of glutamate that offers a very attractive efficacy and safety profile for treating moderate to severe AD. CONCLUSION: The prevention and treatment of vascular risk factors should be an integral part of the management of AD. For the treatment of moderate to severe AD, memantine is a new option that is effective and well tolerated.
OBJECTIVE:Alzheimer disease (AD) is the most common form of dementia. There have been many advances in the pharmacological treatment of AD in recent years. This article discusses 2 of these advances: vascular prevention and a new molecule, memantine. QUALITY OF EVIDENCE: The conclusions and recommendations in this article are based on data from studies providing level I and level II evidence. MAIN MESSAGE: Recent data suggest that vascular disease plays an important role in the physiopathology of AD. Memantine is a non-competitive, low-affinity N-methyl-D-aspartate receptor antagonist of glutamate that offers a very attractive efficacy and safety profile for treating moderate to severe AD. CONCLUSION: The prevention and treatment of vascular risk factors should be an integral part of the management of AD. For the treatment of moderate to severe AD, memantine is a new option that is effective and well tolerated.
Authors: James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp Journal: Lancet Date: 2002-11-23 Impact factor: 79.321
Authors: M A Tedesco; G Ratti; S Mennella; G Manzo; M Grieco; A C Rainone; D Iarussi; A Iacono Journal: Am J Hypertens Date: 1999-11 Impact factor: 2.689